WILMINGTON — With many therapies now in the clinical study phase, Prelude Therapeutics has received state approval to receive $2.6 million from previous grant awards early to aid the companies’ expansion efforts. The early release of state dollars comes at a time when the company continues to grow in its new headquarters and as its
To continue reading this article ...
Subscribe to Delaware Business Times right now and get access to subscriber-only content like this article. Plus get 24 issues of DBT via print or digital, special bonus issues, and discounted registration for our in-person events.